Table of Enhancements.

BioNTech is trialing the world’s first mRNA lung cancer vaccine.

---

1. Antonio Regalado on human-directed self-evolution:

Editing human embryos is restricted in much of the world—and making an edited baby is flatly illegal in most countries surveyed by legal scholars. But advancing technology could render the embryo issue moot. New ways of adding CRISPR to the bodies of people already born—children and adults—could let them easily receive changes as well. Indeed, if you are curious what the human genome could look like in 125 years, it’s possible that many people will be the beneficiaries of multiple rare, but useful, gene mutations currently found in only small segments of the population. These could protect us against common diseases and infections, but eventually they could also yield frank improvements in other traits, such as height, metabolism, or even cognition. These changes would not be passed on genetically to people’s offspring, but if they were widely distributed, they too would become a form of human-directed self-evolution—easily as big a deal as the emergence of computer intelligence or the engineering of the physical world around us.

Some genetic engineers believe that editing embryos, though in theory easy to do, will always be held back by these grave uncertainties. Instead, they say, DNA editing in living adults could become easy enough to be used not only to correct rare diseases but to add enhanced capabilities to those who seek them. If that happens, editing for improvement could spread just as quickly as any consumer technology or medical fad. “I don’t think it’s going to be germline,” says George Church, a Harvard geneticist often sought out for his prognostications. “The 8 billion of us who are alive kind of constitute the marketplace.” For several years, Mr. Church has been circulating what he calls “my famous, or infamous, table of enhancements.” It’s a tally of gene variants that lend people superpowers, including APP and another that leads to extra-hard bones, which was found in a family that complained of not being able to stay afloat in swimming pools. The table is infamous because some believe Church’s inclusion of the HIV-protective CCR5 variant inspired He’s effort to edit it into the CRISPR babies.

Church believes novel gene treatments for very serious diseases, once proven, will start leading the way toward enhancements and improvements to people already born. “You’d constantly be tweaking and getting feedback,” he says—something that’s hard to do with the germline, since humans take so long to grow up. Changes to adult bodies would not be passed down, but Church thinks they could easily count as a form of heredity. He notes that railroads, eyeglasses, cell phones—and the knowledge of how to make and use all these technologies—are already all transmitted between generations. “We’re clearly inheriting even things that are inorganic,” he says. Read the rest. (Sources: technologyreview.com, wyss.harvard.edu, youtube.com, italics mine)

---

2. Doctors have begun trialing the world’s first mRNA lung cancer vaccine in patients, as experts hailed its “groundbreaking” potential to save thousands of lives. Lung cancer is the world’s leading cause of cancer death, accounting for about 1.8m deaths every year. Survival rates in those with advanced forms of the disease, where tumours have spread, are particularly poor. Now experts are testing a new jab that instructs the body to hunt down and kill cancer cells – then prevents them ever coming back. Known as BNT116 and made by BioNTech, the vaccine is designed to treat non-small cell lung cancer (NSCLC), the most common form of the disease. The phase 1 clinical trial, the first human study of BNT116, has launched across 34 research sites in seven countries: the UK, US, Germany, Hungary, Poland, Spain and Turkey. (Sources: theguardian.com, biontech.com)

---

3. On a recent Thursday afternoon, researchers Lanuza Faccioli and Zhiping Hu wheeled an inconspicuous black and white plastic cooler from an operating room at a hospital in downtown Pittsburgh. Inside was a badly scarred liver, just removed from a 47-year-old man undergoing a transplant to receive a new one from a donor. But what if patients could avoid that fate? Faccioli and Hu are part of a University of Pittsburgh team led by Alejandro Soto-Gutiérrez attempting to revive badly damaged livers like these—as well as kidneys, hearts, and lungs. Using messenger RNA, the same technology used in some of the Covid-19 vaccines, they’re aiming to reprogram terminally ill organs to be fit and functioning again. With donor livers in short supply, they think mRNA could one day provide an alternative to transplants. The team plans to begin a clinical trial next year to test the idea in people with end-stage liver disease. (Source: wired.com)

---